帕利哌酮缓释片应用于精神分裂症复发的研究进展  

Research progress of paliperidone extended-release tablets applied in the schizophrenic relapse

作　　者：汪琼华[1] 

机构地区：[1]湖北省孝感市康复医院精神科,432000

出　　处：《中国社区医师》2015年第8期6-7,共2页Chinese Community Doctors

摘　　要：帕利哌酮缓释片作为一种非典型抗精神分裂药物,主要用于精神分裂症急性期的治疗,通过完全阻断5-羟色胺2A受体,部分阻断多巴胺D2受体,来发挥作用。研究证实,帕利哌酮缓释片能够有效缓解精神分裂症阳性症状,改善精神分裂症阴性症状,使精神分裂症患者的依从性、耐受性提高。帕利哌酮缓释片口服后起效迅速,效果明显,治愈率高,能够改善应用其他的非典型抗精神分裂药物治疗无效患者的临床症状。本文对帕利哌酮缓释片应用于精神分裂症复发的研究进展加以综述。Paliperidone extended-release tablet is an atypical antipsychotic drug.It is mainly used in treating the acute phase of schizophrenia.It plays the role through completely blocking the serotonin 2A receptor,partially blocking dopamine D2 receptors.The study confirms that paliperidone extended-release tablets can effectively alleviate the positive symptoms of schizophrenia,improve the negative symptoms of schizophrenia,and improve the compliance and tolerance of schizophrenic patients.Paliperidone extended-release tablets is rapid onset after oral administration,the effect is obvious,the cure rate is high.It can improve the clinical symptoms of patients that the application of other atypical antipsychotic drug treatment is invalid.In this paper,we reviews the research progress of paliperidone extended-release tablets applied in the schizophrenic relapse.

关 键 词：帕利哌酮缓释片 精神分裂症 复发 研究进展 

分 类 号：R749.3[医药卫生—神经病学与精神病学]